Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DXD69J
|
|||
| Drug Name |
AZD2811
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora kinase (AURK) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03366675) AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]. U.S. National Institutes of Health. | |||
| REF 2 | Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016 Feb 10;8(325):325ra17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.